Isolated limb perfusion for locally advanced melanoma in the immunotherapy era

First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.

(2020) Christian U. Blank et al.   JOURNAL OF CLINICAL ONCOLOGY

Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma

(2019) Valerio Belgrano et al.   ANNALS OF SURGICAL ONCOLOGY

1313PD3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)

(2019) C U Blank et al.   ANNALS OF ONCOLOGY

Isolated limb perfusion with melphalan activates interferon-stimulated genes to induce tumor regression in patients with melanoma in-transit metastasis

(2019) Junko Johansson et al.   OncoImmunology

The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies

(2018) H.G. Smith et al.   EUROPEAN JOURNAL OF CANCER

Unleashing endogenous TNF-alpha as a cancer immunotherapeutic

(2018) Steven F. Josephs et al.   Journal of Translational Medicine

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

(2018) Rodabe N. Amaria et al.   NATURE MEDICINE

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

(2018) Christian U. Blank et al.   NATURE MEDICINE

Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma

(2015) H. G. Smith et al.   ANNALS OF SURGICAL ONCOLOGY

Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases

(2015) Jan P. Deroose et al.   MELANOMA RESEARCH

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma

(2015) Andrea Ladányi   Pigment Cell & Melanoma Research

Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion

(2014) Alessandro Testori et al.   JOURNAL OF SURGICAL ONCOLOGY

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spontaneous regression of metastatic melanoma – Clinical evidence of the abscopal effect

(2013) R.J. Bramhall et al.   EJSO

Melan-A specific CD8+ T lymphocytes after hyperthermic isolated limb perfusion: A pilot study in patients with in-transit metastases of malignant melanoma

(2013) Roger Olofsson et al.   INTERNATIONAL JOURNAL OF HYPERTHERMIA

Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma

(2013) Roger Olofsson et al.   INTERNATIONAL JOURNAL OF HYPERTHERMIA

Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis

(2013) Hong Nie et al.   NATURE MEDICINE

20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters

(2011) Jan P. Deroose et al.   ANNALS OF SURGICAL ONCOLOGY

Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases

(2011) J. P. Deroose et al.   BRITISH JOURNAL OF SURGERY

Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and Safety

(2010) D. Moreno-Ramirez et al.   ONCOLOGIST